Article

Fractional versus standard BNT162b2 boosters after non-mRNA priming in Mongolia: 24-month immunogenicity and safety evidence from a randomised controlled trial

2025-09-07

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> Booster doses of COVID-19 vaccines help restore protection against waning immunity and emerging variants. Having found that fractional BNT162b2 boosters were non-inferior to standard boosters in eliciting anti-spike IgG responses at day 28 in Mongolian adults, we assessed long-term immunogenicity and safety in the same cohort. <h4>Methods</h4> In this randomised, controlled,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4c7609a9-ecf8-582f-960b-52e6b2541ed4
DOI: 10.1101/2025.09.04.25335126

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Fractional versus standard BNT162b2 boosters after non-mRNA priming in Mongolia: 24-month immunogenicity and safety evidence from a randomised controlled trialDOI 10.1101/2025.09.04.25335126Read

Twelve-month follow-up of immunogenicity and safety of fractional and standard booster doses of the Pfizer-BioNTech COVID-19 vaccine in adults primed with ChAdOx1, BBIBP-CorV, or GAM-CoV-Vac: a randomised controlled trialSemantic proximity Read

Immunogenicity, Safety, and Reactogenicity of a Half- Versus Full-Dose BNT162b2 (Pfizer-Biontech) Booster Following a Two-Dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac Priming Schedule in Mongolia: A Randomised, Controlled, Non-Inferiority TrialSemantic proximity Read

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in QatarSemantic proximity Read

Extended interval BNT162b2 vaccination enhances peak antibody generation in older peopleSemantic proximity Read

Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster doseSemantic proximity Read

BNT162b2 vaccine booster dose protection: A nationwide study from IsraelSemantic proximity Read

Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trialSemantic proximity Read

Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS StudySemantic proximity Read

Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster doseSemantic proximity Read

Effectiveness of BNT162b2 booster doses in England: an observational study in OpenSAFELY-TPPSemantic proximity Read

Immunogenicity and Safety of BNT162b2 mRNA Vaccine in Chinese Adults: A Randomized Clinical TrialSemantic proximity Read

The Immunogenicity and Safety of Different COVID-19 Booster Vaccination Following CoronaVac or ChAdOx1 nCoV-19 Primary SeriesSemantic proximity Read